ATAI: Investor Sentiment and Bull/Bear Views
AtaiBeckley Inc.
Loading...
Loading...
Buzzberg insights
Attention & activity
- unique authors
- 1
- vs usual
- New
24h1
30d avg / day0
- unique authors
- 1
- vs usual
- New
7d1
4wk avg / week0
Author calls
What authors recommend
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
Author positions
What authors disclose
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
Feed & authors
- ideas
- 18
- Authors
- 16
- Sources
- 15
Call performance
Performance since each author’s call.
| Author | Direction | Return |
|---|---|---|
| No data yet | ||
Best calls over the past year · return since each call
Company facts
- Market cap
- $2.73B 2026-09-15
Financial results are not available yet.
Financial details
Market cap · yahoo · 2026-09-15
Sentiment
Attention
1Newvs usual
unique authors
30d avg / day 0
Attention
1Newvs usual
unique authors
4wk avg / week 0
Loading chart...
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
02:29
Jun 23
Jun 23
Real Vision
YouTube
Atai psilocybin catalyst could reprice higher.
Atai Life Sciences is awaiting psilocybin results just after summer, potentially in August, which could reprice the stock higher. He frames it as another pipeline catalyst in the psychedelic therapeutics theme that his pro portfolio has been early in.
05:43
Apr 19
Apr 19
r/wallstreetbets
Reddit
The author claims "Psychedelics getting Trump sign off," implying favorable regulatory changes.
The author claims "Psychedelics getting Trump sign off," implying favorable regulatory changes. If regulatory approval accelerates, companies like ATAI (Atai Life Sciences) working on psychedelic therapies could see increased investor interest and valuation. The author is holding and believes the uptrend will continue, making it a long opportunity based on policy sentiment. The post provides zero evidence; political news may be misinterpreted or irrelevant. Regulatory paths are long and uncertain. Stock is highly volatile and speculative.
18:16
Apr 18
Apr 18
r/wallstreetbets
Reddit
Trump's EO directs FDA to accelerate psychedelic reviews.
Trump's EO directs FDA to accelerate psychedelic reviews; ATAI's lead asset BPL-003 has Breakthrough Therapy Designation and is about to start Phase 3. The company could receive a national priority voucher next week, drastically compressing the approval timeline and attracting institutional capital. Regulatory risk has plummeted, Phase 3 is imminent, and the stock is poised for a re-rating with massive analyst upside. Phase 3 trial failure, voucher not awarded, broader market sell-off affecting speculative biotech.